{"id":32960,"date":"2023-12-28T10:09:10","date_gmt":"2023-12-28T10:09:10","guid":{"rendered":"https:\/\/celonpharma.com\/?p=32960"},"modified":"2023-12-28T10:09:10","modified_gmt":"2023-12-28T10:09:10","slug":"current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/","title":{"rendered":"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.<br>Date prepared: 12\/22\/2023, 10:59 a.m.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, which is linked to the Company awaiting a significant growth in sales in the generic segment, the Management Board of Celon Pharma S.A. (the \u201cCompany\u201d), hereby announces that it was informed about the decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products of December 21, 2023 concerning the issuance of marketing authorisation for one of the Company&#8217;s products in this therapeutic category.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It constitutes a standard procedure element foreseen and required by pharmaceutical law. The decision of the aforementioned authority is not tantamount to launching of manufacture and sale of the product, however it does constitute an element necessary for its future marketing in Poland.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.Date prepared: 12\/22\/2023, 10:59 a.m. In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, which<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\" title=\"ReadCurrent Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":31749,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-32960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-report"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.Date prepared: 12\/22\/2023, 10:59 a.m. In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, whichRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-28T10:09:10+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1050\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\",\"url\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\",\"name\":\"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png\",\"datePublished\":\"2023-12-28T10:09:10+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage\",\"url\":\"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png\",\"contentUrl\":\"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png\",\"width\":1050,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/","og_locale":"en_US","og_type":"article","og_title":"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP","og_description":"Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.Date prepared: 12\/22\/2023, 10:59 a.m. In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, whichRead more &raquo;","og_url":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/","og_site_name":"CelonGROUP","article_published_time":"2023-12-28T10:09:10+00:00","og_image":[{"width":1050,"height":600,"url":"http:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","type":"image\/png"}],"author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/","url":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/","name":"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"primaryImageOfPage":{"@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage"},"image":{"@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage"},"thumbnailUrl":"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","datePublished":"2023-12-28T10:09:10+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#primaryimage","url":"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","contentUrl":"https:\/\/celon.group\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","width":1050,"height":600},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2023\/12\/28\/current-report-no-24-2023-decision-of-the-president-of-the-office-for-registration-regarding-the-marketing-authorization-for-a-medicinal-product-of-the-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Current Report No. 24\/2023 \u2013 Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/32960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=32960"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/32960\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media\/31749"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=32960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=32960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=32960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}